CLINICAL TRIALS PROFILE FOR POTELIGEO

All Clinical Trials for POTELIGEO

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04848064 ↗	Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma	Recruiting	John Reneau	Phase 1	2021-11-01	This phase I trial is to find out the best dose, possible benefits and/or side effects of third-party natural killer cells in combination with mogamulizumab in treating patients with cutaneous T-cell lymphoma or adult T-cell leukemia/lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with third-party natural killer cells, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Mogamulizumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving third-party natural killer cells in combination with mogamulizumab may kill more cancer cells.
NCT05956041 ↗	Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas	Recruiting	Hoosier Cancer Research Network	Phase 2	2023-12-06	This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter. Subjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.
NCT05956041 ↗	Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas	Recruiting	Merck Sharp & Dohme LLC	Phase 2	2023-12-06	This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter. Subjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.
NCT05956041 ↗	Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas	Recruiting	University of Michigan Rogel Cancer Center	Phase 2	2023-12-06	This is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter. Subjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.

Clinical Trial Conditions for POTELIGEO

Condition Name

Condition Name for POTELIGEO
Intervention	Trials
Fungoides Mycosis Sezary Syndrome	1
Mycosis Fungoides	1
Recurrent Adult T-Cell Leukemia/Lymphoma	1
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	1

Condition MeSH

Condition MeSH for POTELIGEO
Intervention	Trials
Lymphoma	3
Lymphoma, T-Cell	3
Lymphoma, T-Cell, Peripheral	2
Lymphoma, T-Cell, Cutaneous	2

Clinical Trial Locations for POTELIGEO

Trials by Country

Trials by Country for POTELIGEO
Location	Trials
United States	4

Trials by US State

Trials by US State for POTELIGEO
Location	Trials
Florida	1
Connecticut	1
Michigan	1
Ohio	1

Clinical Trial Progress for POTELIGEO

Clinical Trial Phase

Clinical Trial Phase for POTELIGEO
Clinical Trial Phase	Trials
Phase 2	2
Phase 1	1
EARLY_PHASE1	1

Clinical Trial Status

Clinical Trial Status for POTELIGEO
Clinical Trial Phase	Trials
Recruiting	3
Not yet recruiting	1

Clinical Trial Sponsors for POTELIGEO

Sponsor Name

Sponsor Name for POTELIGEO
Sponsor	Trials
Kyowa Hakko Kirin Pharma, Inc.	1
H. Lee Moffitt Cancer Center and Research Institute	1
John Reneau	1

Sponsor Type

Sponsor Type for POTELIGEO
Sponsor	Trials
Other	5
Industry	3

POTELIGEO Market Analysis and Financial Projection

Last updated: February 9, 2026

Clinical Trials Update for POTELIGEO

POTELIGEO (belantamab mafodotin) is an anti-BCMA (B-cell maturation antigen) therapy developed by GlaxoSmithKline for multiple myeloma. Its clinical development has proceeded through several phases, primarily targeting relapsed or refractory multiple myeloma (RRMM).

Completed and Ongoing Trials

• Phase 1/2 DREAMM-1 and DREAMM-2

  • DREAMM-1: Demonstrated initial safety and efficacy with overall response rates (ORR) of approximately 60%. The trial included 35 heavily pretreated patients. Trade-offs involved ocular toxicity leading to dosage modifications.

  • DREAMM-2: Enrolled 196 patients with relapsed/refractory multiple myeloma (RRMM). Achieved ORR of 31% at the 2.5 mg/kg dose, with a median duration of response of 11 months. The trial used single-agent belantamab mafodotin.

• Phase 3 DREAMM-3

  • Initiated to compare POTELIGEO plus standard therapy versus standard therapy alone in newly diagnosed multiple myeloma. Results are pending.

• Combination Trials

  • DREAMM-4: Combines POTELIGEO with pembrolizumab. Results are under interim analysis; key endpoints include safety and response rate.

  • DREAMM-5: Investigates multiple combinations, including with immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). Data expected over 2023-2024.

Regulatory Status

• FDA: Approved for relapsed/refractory multiple myeloma in August 2020, with a boxed warning regarding ocular toxicity. Requires regular eye exams.

• EMA: Approved in the European Union in 2021 under similar conditions.

• Post-approval: Focuses on real-world safety data, especially ocular adverse events and management protocols.

Market Analysis

Market Size and Growth

The global multiple myeloma therapeutics market was valued at approximately USD 8.1 billion in 2022, projected to reach USD 12.4 billion by 2030, growing at a compound annual growth rate (CAGR) of 6%. The major drivers include increased prevalence, better diagnostics, and novel therapies such as antibody-drug conjugates.

Competitive Landscape

POTELIGEO competes primarily with other BCMA-targeted therapies:

Drug	Mechanism	Status	Key Data
CARVYKTI (idecabtagene vicleucel)	CAR T-cell therapy	Approved for RRMM in 2021	ORR 73%, median progression-free survival (PFS) of 8.8 months
Abecma (idecabtagene vicleucel)	CAR T-cell therapy	Approved 2021	Similar efficacy data, higher CRS risk
teclistamab	Bispecific antibody	Approved in 2022	ORR ~63%, manageable safety profile
Belantamab mafodotin (POTELIGEO)	Antibody-drug conjugate	Approved 2020	ORR ~31%, ocular toxicity as common adverse event

Pricing and Reimbursement

In the U.S., POTELIGEO's list price is approximately USD 4,450 per dose, administered every three weeks. Cost-effectiveness varies based on efficacy, toxicity management, and reimbursement policies.

Market Challenges

• Ocular toxicity management: Limits dosing flexibility and patient adherence.
• Competition from cell therapies: CAR T-cells offer durable remissions but face logistical hurdles.

Future Market Projections

By 2030, antibody-drug conjugate-based therapies like POTELIGEO could capture a significant market share, especially if toxicity management improves and efficacy data expand through ongoing trials.

Strategic Opportunities

• Development of combination regimens to improve response rates.
• Enhanced patient selection to mitigate ocular adverse events.
• Expansion into earlier lines of therapy with supportive clinical data.

Summary of Financial Outlook

GSK recognizes POTELIGEO as a front-runner in BCMA-targeted antibody-drug conjugates. The drug’s revenue depends on expanding approved indications, managing safety issues, and competing with emerging therapies such as bispecific antibodies and CAR T-cells.

Key Takeaways

• POTELIGEO has demonstrated efficacy in relapsed/refractory multiple myeloma but is limited by ocular toxicity.
• The drug gained regulatory approval in 2020; ongoing and future trials target combination therapies and earlier disease stages.
• The multiple myeloma therapeutic market is expanding, with antibody-drug conjugates competing alongside CAR T-cell therapies.
• Market growth depends on improved toxicity management, expanding indications, and competitive positioning.
• Price points are comparable with other labeled biologics, but reimbursement and treatment protocols influence uptake.

FAQs

1. What are the main safety concerns with POTELIGEO?

Ocular toxicity, specifically keratopathy, causes blurred vision and dry eyes, leading to dose delays and reductions.

2. How does POTELIGEO compare to CAR T therapies?

It offers off-the-shelf convenience and manageable adverse effects but tends to have lower response durability compared to CAR T-cells.

3. Are there ongoing trials exploring earlier treatment lines?

Yes, DREAMM-3 and DREAMM-4 trials aim to evaluate POTELIGEO in new settings, including newly diagnosed and combination regimens.

4. What are the key differentiators for POTELIGEO in the market?

It is an approved, commercially available antibody-drug conjugate for RRMM, with proven efficacy and regulatory acceptance since 2020.

5. What strategies could improve market penetration?

Enhancing toxicity management, expanding indications, and developing combination therapies could increase adoption.

References

1. GSK. (2020). FDA approves Blenrep (belantamab mafodotin-blmf) for multiple myeloma. [FDA Press Release].

2. Bloomberg Intelligence. (2023). Multiple myeloma therapeutics market analysis.

3. ClinicalTrials.gov. (2023). Belantamab mafodotin trials.

4. European Medicines Agency. (2021). Summary of opinion for Blenrep.

5. IQVIA. (2023). Oncology drug market forecast.